tradingkey.logo

Trinity Biotech PLC

TRIB
View Detailed Chart
1.020USD
-0.260-20.31%
Close 12/24, 13:00ETQuotes delayed by 15 min
8.46MMarket Cap
LossP/E TTM

Trinity Biotech PLC

1.020
-0.260-20.31%
Intraday
1m
30m
1h
D
W
M
D

Today

-20.31%

5 Days

+10.15%

1 Month

+15.25%

6 Months

+45.71%

Year to Date

+15.88%

1 Year

+23.26%

View Detailed Chart

TradingKey Stock Score of Trinity Biotech PLC

Currency: USD Updated: 2025-12-24

Key Insights

Trinity Biotech PLC's fundamentals are relatively weak, and its growth potential is significant.Its valuation is considered fairly valued, ranking 151/206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Trinity Biotech PLC's Score

Industry at a Glance

Industry Ranking
151 / 206
Overall Ranking
447 / 4562
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Trinity Biotech PLC Highlights

StrengthsRisks
Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
Growing
The company is in a growing phase, with the latest annual income totaling USD 61.55M.
Fairly Valued
The company’s latest PE is -0.20, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 972.36K shares, increasing 42.50% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 171.36K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 8.62.

Trinity Biotech PLC News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Trinity Biotech PLC Info

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
Ticker SymbolTRIB
CompanyTrinity Biotech PLC
CEOGillard (John)
Websitehttps://www.trinitybiotech.com/

FAQs

What is the current price of Trinity Biotech PLC (TRIB)?

The current price of Trinity Biotech PLC (TRIB) is 1.020.

What is the symbol of Trinity Biotech PLC?

The ticker symbol of Trinity Biotech PLC is TRIB.

What is the 52-week high of Trinity Biotech PLC?

The 52-week high of Trinity Biotech PLC is 3.440.

What is the 52-week low of Trinity Biotech PLC?

The 52-week low of Trinity Biotech PLC is 0.480.

What is the market capitalization of Trinity Biotech PLC?

The market capitalization of Trinity Biotech PLC is 8.46M.

What is the net income of Trinity Biotech PLC?

The net income of Trinity Biotech PLC is -31.79M.

Is Trinity Biotech PLC (TRIB) currently rated as Buy, Hold, or Sell?

According to analysts, Trinity Biotech PLC (TRIB) has an overall rating of --, with a price target of --.

What is the Earnings Per Share (EPS TTM) of Trinity Biotech PLC (TRIB)?

The Earnings Per Share (EPS TTM) of Trinity Biotech PLC (TRIB) is -5.137.
KeyAI